Glenda Canderan

Glenda Canderan

Auto-generated profile, based on publicly available information

Glenda Canderan

Department of Medicine, University of Virginia School of Medicine, Charlottesville, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2023 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
RMRoshell Muir
Roshell Muir
TMTalibah Metcalf
Talibah Metcalf
SFSlim Fourati
Slim Fourati
YBYannic Bartsch
Yannic Bartsch
JKJacqueline Kyosiimire-Lugemwa
Jacqueline Kyosiimire-Lugemwa
EHElias K Haddad
Elias K Haddad
Schistosomiasis is a disease caused by parasitic flatworms of the Schistosoma spp., and is increasingly recognized to alter the immune system, and the potential to respond to vaccines. The impact of endemic infections on protective immunity is critical to inform vaccination strategies globally. We assessed the influence of Schistosoma mansoni worm burden on multiple host vaccine-related immune parameters in a Ugandan fishing cohort (n = 75) given three doses of a Hepatitis B (HepB) vaccine at baseline and multiple timepoints post-vaccination. We observed distinct differences in immune responses in instances of higher worm burden, compared to low worm burden or non-infected. Concentrations of pre-vaccination serum schistosome-specific circulating anodic antigen (CAA), linked to worm burden, showed a significant bimodal distribution associated with HepB titers, which was lower in individuals with higher CAA values at month 7 post-vaccination (M7). Comparative chemokine/cytokine responses revealed significant upregulation of CCL19, CXCL9 and CCL17 known to be involved in T cell activation and recruitment, in higher CAA individuals, and CCL17 correlated negatively with HepB titers at month 12 post-vaccination. We show that HepB-specific CD4+ T cell memory responses correlated positively with HepB titers at M7. We further established that those participants with high CAA had significantly lower frequencies of circulating T follicular helper (cTfh) subpopulations pre- and post-vaccination, but higher regulatory T cells (Tregs) post-vaccination, suggesting changes in the immune microenvironment in high CAA could favor Treg recruitment and activation. Additionally, we found that changes in the levels of innate-related cytokines/chemokines CXCL10, IL-1β, and CCL26, involved in driving T helper responses, were associated with increasing CAA concentration. This study provides further insight on pre-vaccination host responses to Schistosoma worm burden which will support our understanding of vaccine responses altered by pathogenic host immune mechanisms and memory function and explain abrogated vaccine responses in communities with endemic infections.

1 September 2010 in Current Opinion in HIV and AIDS
Verified
Journal Article
Open access
HPHélène Perrin
Hélène Perrin
GCGlenda Canderan
Glenda Canderan
RSRafick-Pierre Sékaly
Rafick-Pierre Sékaly
LTLydie Trautmann
Lydie Trautmann
Purpose of review Following the evidence that T-cell responses are crucial in the control of HIV-1 infection, vaccines targeting T-cell responses were tested in recent clinical trials. However, these vaccines showed a lack of efficacy. This review attempts to define the qualitative and quantitative features that are desirable for T-cell-induced responses by vaccines. We also describe strategies that could lead to achievement of this goal. Recent findings Using the yellow fever vaccine as a benchmark of an efficient vaccine, recent studies identified factors of immune protection and more importantly innate immune pathways needed for the establishment of long-term protective adaptive immunity. Summary To prevent or control HIV-1 infection, a vaccine must induce efficient and persistent antigen-specific T cells endowed with mucosal homing capacity. Such cells should have the capability to counteract HIV-1 diversity and its rapid spread from the initial site of infection. To achieve this goal, the activation of a diversified innate immune response is critical. New systems biology approaches will provide more precise correlates of immune protection that will pave the way for new approaches in T-cell-based vaccines.

17 December 2009 in Immunotherapy
Verified
Journal Article
Closed access
GCGlenda Canderan
Glenda Canderan
PDPaolo Dellabona
Paolo Dellabona
Evaluation of: Martin-Orozco N, Muranski P, Chung Y et al.: T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31(5), 787-798 (2009). The immune system plays an important role in tumor control. Tumor antigen-specific CD4(+) and CD8(+) T cells are being actively exploited in cancer immunotherapy protocols that often attain clinical responses. The T helper (Th)1 effector cytokine profile, epitomized by the production of IFN-gamma, is considered the optimal pathway in controlling tumor growth. In this study, Martin-Orozco challenges this notion by demonstrating that newly defined Th17 effector T cells display a stronger anti-tumor effect vis a vis with Th1 cells. Th17 cells produce the strongly inflammatory cytokines IL-17A and IL-17F, and so far have been implicated in the response to infectious pathogens and in autoimmunity. This study reveals that Th17 cells protect against cancer, not only by triggering a potent nonantigen-specific intratumor inflammatory infiltrate, but also, and remarkably, by providing a more significant help than Th1 cells for the efficient induction, expansion, differentiation and tumor homing of tumor-specific CD8(+) T cells. This study, therefore, sheds new light on the effector functions of Th17 cells and has strong implications for their translation into clinical applications for cancer immunotherapy.

26 March 2025 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
GCGlenda Canderan
Glenda Canderan
LMLyndsey M. Muehling
Lyndsey M. Muehling
AKAlexandra Kadl
Alexandra Kadl
SLShay Ladd
Shay Ladd
CBCatherine Bonham
Catherine Bonham
JWJudith A. Woodfolk
Judith A. Woodfolk

26 July 2023 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
EAEmily C. Ayers
Emily C. Ayers
GCGlenda Canderan
Glenda Canderan
MWMichael E. Williams
Michael E. Williams
BKBehnam Keshavarz
Behnam Keshavarz
CPCraig A. Portell
Craig A. Portell
JWJudith A. Woodfolk
Judith A. Woodfolk